Drug intelligence / Profile preview

MAb52-29.1

Development stage: Preclinical
Lead developer: MedAbome
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

MAb52-29.1 is a monoclonal antibody developed by Medabome for the treatment of solid tumors, classified under neoplasms. The drug is currently in preclinical development and has not yet advanced to clinical trials or received regulatory approval. Its precise mechanism of action, molecular target, and further pharmacological details have not been disclosed publicly as of June 2025[1][2].

Beyond the preview

Go deeper on MAb52-29.1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAb52-29.1.

Explore the full profile